A new genetic biomarker to predict immunotherapy success
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
List view / Grid view
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
As humanity faces an impending era of pandemics, global collaboration among governments, organisations and industry is critical. In this article, epidemiologist Dr Jay Varma explores the urgent need for researching and developing drugs to combat a range of epidemic-prone pathogens, and reflects on the increased risk of spillovers and the…
Using an advanced human heart organoid system, researchers found the contributing factors to the condition and possible therapeutic compounds.
In light of the International Day for Women and Girls in Science, we had the privilege of speaking to Dr Jane Kendrew, Director of Translational Oncology at Sygnature Discovery. With over 30 years of drug discovery experience, she shares many insights, including her inspiration to pursue a career in STEM,…
The International Day for Women and Girls in Science: we have the privilege of engaging with Denise Bowser, a distinguished figure with a remarkable journey at Onyx Scientific. Join us as we explore Denise's experiences, the milestones and challenges she has encountered while navigating the dynamic landscape of the pharmaceutical…
In this Q&A, founder of Scheer Medical Wellness Dr Alexander Scheer shares his insights, discussing the current challenges in stem cell therapy and how these can be addressed, the advancements in delivery techniques, and stem cells’ overall potential in regenerative medicine.
This eBook explores a new means to perform single-cell functional analysis. Uncover the Xdrop®single-cell format workflow with its ability to help identify, quantify, and comprehend immune cell functions at the individual cellular level.
New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
In this Q&A, Dr Gerard Wong elucidates the inflammatory capacity of fragmented viral components from the perspective of supramolecular self-organisation.
While blood tests measuring prostate-specific antigen (PSA) levels have been a primary screening tool, their limitations in specificity have led to challenges such as overdiagnosis and overtreatment. Cleveland Diagnostics is pioneering an alternative approach with the IsoPSA test, focusing on assessing the structure of the PSA protein rather than its…
Distinct macrophage signatures that align specifically with regeneration could offer novel therapies to enhance wound healing.
In this Q&A, Keith Murphy, CEO of Organovo, discusses how the shift from animal models to 3D human tissues can transform the preclinical space. Among his many insights, he details the limitations of animal models, how Organovo’s 3D human tissue models facilitate a deeper understanding of genetic expression within specific…
In the world of neuroscience, where the unmet medical need is vast and diverse, the journey to develop and commercialise treatments for neurological diseases, including rare conditions, is fraught with challenges. In this insightful interview with Dr Bruce Leuchter, President and CEO at Neurvati Neurosciences, with over two decades of…
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. This month we interview Dr Sara Sangha, Associate Vice President of Medical Affairs and Head of US Medical Aesthetics at AbbVie. Over her almost 20 years with Allergan…
Morphine is a frequently used analgesic that activates the mu-opioid receptor (MOR), which has prominent side effects of tolerance. A monoclonal antibody (mAb) precisely targeting MOR, named as 3A5C7, was developed to treat morphine tolerance by enhancing morphine-induced MOR endocytosis via GRK2/β-arrestin2 pathway. In this Q&A session with Dr Jia-Jia…